Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARDELYX, INC.ARDX · Entity 4972 | Director | June 16, 2026 | June 18, 2026 |
| Akari Therapeutics PlcAKTX · Entity 7692 | Director | December 16, 2025 | December 19, 2025 |
| Epizyme, Inc.EPZM · Entity 12703 | Director · President & CEO | March 25, 2021 | March 29, 2021 |
| Nuvation Bio Inc.NUVB · Entity 4384 | Director | May 21, 2026 | May 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARDELYX, INC.
Report date June 16, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 68,006 |
Reported balance
After 2026-06-16 transaction · row 1
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 26,455 · Balance 68,006 F1: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) share of Common Stock for each one (1) RSU upon the vesting thereof. The RSUs were issued pursuant to the Issuer's Non-Employee Director Compensation Program. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.67 · Expires 2036-06-16 | Direct | 39,715 |
Reported balance
After 2026-06-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-16 · Grant · Acquired 39,715 · Balance 39,715 F2: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F3: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) share of Common Stock for each one (1) RSU upon the vesting thereof. The RSUs were issued pursuant to the Issuer's Non-Employee Director Compensation Program.
F2: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program.
F3: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date.
Akari Therapeutics Plc
Report date December 16, 2025 · Filed December 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Warrants to purchase American Depositary Shares ("ADRs")SEC Table II · derivative / convertible security · Conversion / exercise price $0.39 | Direct | 123,731 |
Reported balance
After 2025-12-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-16 · Purchase · Acquired 123,731 · Balance 123,731 F1: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer. F2: On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 123,731 ADSs (the "PIPE PFWs" and ) and (ii) accompanying Series G Warrants to purchase up to 123,731 ADSs (the "Series G Warrants"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended. F4: The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041. F3: The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised. |
| Pre-Funded Warrants to purchase ADRsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 123,731 |
Reported balance
After 2025-12-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-12-16 · Purchase · Acquired 123,731 · Balance 123,731 F1: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer. F2: On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 123,731 ADSs (the "PIPE PFWs" and ) and (ii) accompanying Series G Warrants to purchase up to 123,731 ADSs (the "Series G Warrants"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended. F7: Conversion Exercise Price of Security is $0.00001 F4: The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041. F3: The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised. |
| Pre-Funded Warrants to purchase ADRsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 30,932 |
Reported balance
After 2025-12-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-12-16 · Purchase · Acquired 30,932 · Balance 30,932 F1: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer. F5: On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 30,932 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 32,191 ADSs (the "Note Exchange Unregistered Warrants"). F7: Conversion Exercise Price of Security is $0.00001 F6: The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised. |
| Warrants to purchase ADRsSEC Table II · derivative / convertible security · Conversion / exercise price $0.39 | Direct | 30,932 |
Reported balance
After 2025-12-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-12-16 · Purchase · Acquired 30,932 · Balance 30,932 F1: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer. F5: On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 30,932 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 32,191 ADSs (the "Note Exchange Unregistered Warrants"). F6: The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised. |
Filing footnotes · ownership attribution and instrument terms
F1: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer.
F2: On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 123,731 ADSs (the "PIPE PFWs" and ) and (ii) accompanying Series G Warrants to purchase up to 123,731 ADSs (the "Series G Warrants"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended.
F3: The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised.
F4: The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041.
F5: On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 30,932 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 32,191 ADSs (the "Note Exchange Unregistered Warrants").
F6: The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised.
F7: Conversion Exercise Price of Security is $0.00001
Epizyme, Inc.
Report date March 25, 2021 · Filed March 29, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001SEC Table I · non-derivative | Direct | 322,626 |
Reported balance
After 2021-03-25 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-03-25 · Sale · Disposed 10,328 · Balance 322,626 F1: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted under the Issuer's 2013 Stock Incentive Plan on March 24, 2020. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the reporting person. F2: The Reporting Person acquired 977 shares of common stock under the Issuer's 2013 Employee Stock Purchase Plan on February 28, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted under the Issuer's 2013 Stock Incentive Plan on March 24, 2020. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the reporting person.
F2: The Reporting Person acquired 977 shares of common stock under the Issuer's 2013 Employee Stock Purchase Plan on February 28, 2021.
Nuvation Bio Inc.
Report date May 21, 2026 · Filed May 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.79 · Expires 2036-05-20 | Direct | 123,397 |
Reported balance
After 2026-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 123,397 · Balance 123,397 F1: 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 21, 2026); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 21, 2026); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Neon Therapeutics, Inc.
Report date May 06, 2020 · Filed May 06, 2020
Section 16 reporting ended · disclosed 2020-05-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.56 | Direct | 0 |
Reported balance
After 2020-05-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-05-06 · Disposition to issuer · Disposed 28,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 15, 2020, by and among the Issuer, BioNTech SE ("BioNTech"), and Endor Lights, Inc. a direct wholly owned subsidiary of BioNTech ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of May 6, 2020 (the "Effective Time"), at the Effective Time these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration"). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.64 | Direct | 0 |
Reported balance
After 2020-05-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-05-06 · Disposition to issuer · Disposed 18,500 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 15, 2020, by and among the Issuer, BioNTech SE ("BioNTech"), and Endor Lights, Inc. a direct wholly owned subsidiary of BioNTech ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of May 6, 2020 (the "Effective Time"), at the Effective Time these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration"). |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 15, 2020, by and among the Issuer, BioNTech SE ("BioNTech"), and Endor Lights, Inc. a direct wholly owned subsidiary of BioNTech ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of May 6, 2020 (the "Effective Time"), at the Effective Time these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration").
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 16, 2026 Filed Jun 18, 2026 20:01 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 39,715 | $0.00 Strike: $5.67 | $0.00 |
DisclosureSEC source: 0001620152-26-000005 · wk-form4_1781812867.xml · derivative · entry 2 Bazemore Robert B · CIK 0001620152 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,715 Underlying: Common Stock · 39,715 shares Expires 2036-06-16 F2 · shares: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F3 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. Read SEC document |
| June 16, 2026 Filed Jun 18, 2026 20:01 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantCommon Stock | 26,455 | $0.00 | $0.00 |
DisclosureSEC source: 0001620152-26-000005 · wk-form4_1781812867.xml · nonDerivative · entry 1 Bazemore Robert B · CIK 0001620152 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,006 F1 · shares: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) share of Common Stock for each one (1) RSU upon the vesting thereof. The RSUs were issued pursuant to the Issuer's Non-Employee Director Compensation Program. Read SEC document |
| May 21, 2026 Filed May 27, 2026 00:03 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantStock Option (Right to Buy) · Derivative | 123,397 | $0.00 Strike: $4.79 | $0.00 |
DisclosureSEC source: 0001620152-26-000003 · form4-05272026_120523.xml · derivative · entry 1 Bazemore Robert B · CIK 0001620152 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,397 Underlying: Class A Common Stock · 123,397 shares Expires 2036-05-20 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 21, 2026); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date. Read SEC document |
| December 16, 2025 Filed Dec 19, 2025 02:56 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | PurchasePre-Funded Warrants to purchase ADRs · Derivative | 30,932 | $0.40 Strike: $0.00 | $12,499.62 |
DisclosureSEC source: 0001493152-25-028416 · ownership.xml · derivative · entry 4 Bazemore Robert B · CIK 0001620152 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,932 Underlying: American Depositary Shares representing Ordinary Shares · 30,932 shares Expires not disclosed F1 · security: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer. F5 · security: On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 30,932 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 32,191 ADSs (the "Note Exchange Unregistered Warrants"). F7 · derivative.exercise_price: Conversion Exercise Price of Security is $0.00001 F5 · price: On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 30,932 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 32,191 ADSs (the "Note Exchange Unregistered Warrants"). F6 · derivative.exercise_date: The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised. F6 · derivative.expiration_date: The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised. Read SEC document |
| December 16, 2025 Filed Dec 19, 2025 02:56 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | PurchaseWarrants to purchase ADRs · Derivative | 30,932 | Not disclosed Strike: $0.39 | Not disclosed |
DisclosureSEC source: 0001493152-25-028416 · ownership.xml · derivative · entry 3 Bazemore Robert B · CIK 0001620152 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,932 Underlying: American Depositary Shares representing Ordinary Shares · 30,932 shares Expires not disclosed F1 · security: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer. F5 · security: On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 30,932 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 32,191 ADSs (the "Note Exchange Unregistered Warrants"). F5 · price: On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 30,932 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 32,191 ADSs (the "Note Exchange Unregistered Warrants"). F6 · derivative.exercise_date: The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised. F6 · derivative.expiration_date: The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised. Read SEC document |
| December 16, 2025 Filed Dec 19, 2025 02:56 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | PurchasePre-Funded Warrants to purchase ADRs · Derivative | 123,731 | $0.40 Strike: $0.00 | $49,999.70 |
DisclosureSEC source: 0001493152-25-028416 · ownership.xml · derivative · entry 2 Bazemore Robert B · CIK 0001620152 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,731 Underlying: American Depositary Shares representing Ordinary Shares · 123,731 shares Expires not disclosed F1 · security: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer. F2 · security: On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 123,731 ADSs (the "PIPE PFWs" and ) and (ii) accompanying Series G Warrants to purchase up to 123,731 ADSs (the "Series G Warrants"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended. F7 · derivative.exercise_price: Conversion Exercise Price of Security is $0.00001 F4 · price: The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041. F3 · derivative.exercise_date: The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised. F3 · derivative.expiration_date: The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised. Read SEC document |
| December 16, 2025 Filed Dec 19, 2025 02:56 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | PurchaseWarrants to purchase American Depositary Shares ("ADRs") · Derivative | 123,731 | Not disclosed Strike: $0.39 | Not disclosed |
DisclosureSEC source: 0001493152-25-028416 · ownership.xml · derivative · entry 1 Bazemore Robert B · CIK 0001620152 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,731 Underlying: American Depositary Shares representing Ordinary Shares · 123,731 shares Expires not disclosed F1 · security: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer. F2 · security: On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 123,731 ADSs (the "PIPE PFWs" and ) and (ii) accompanying Series G Warrants to purchase up to 123,731 ADSs (the "Series G Warrants"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended. F4 · price: The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041. F3 · derivative.exercise_date: The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised. F3 · derivative.expiration_date: The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised. Read SEC document |
| June 18, 2025 Filed Jun 24, 2025 00:44 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 54,059 | $0.00 Strike: $3.61 | $0.00 |
DisclosureSEC source: 0001628280-25-032730 · wk-form4_1750725839.xml · derivative · entry 2 Bazemore Robert B · CIK 0001620152 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,059 Underlying: Common Stock · 54,059 shares Expires 2035-06-18 F2 · shares: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F3 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. Read SEC document |
| June 18, 2025 Filed Jun 24, 2025 00:44 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantCommon Stock | 41,551 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-032730 · wk-form4_1750725839.xml · nonDerivative · entry 1 Bazemore Robert B · CIK 0001620152 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,551 F1 · shares: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) shares of Common Stock for each one (1) RSU upon the vesting thereof. The RSUs were issued pursuant to the Issuer's Non-Employee Director Compensation Program. Read SEC document |
| May 21, 2025 Filed May 23, 2025 20:05 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantStock Option (Right to Buy) · Derivative | 292,983 | $0.00 Strike: $2.03 | $0.00 |
DisclosureSEC source: 0001415889-25-014416 · form4-05232025_040501.xml · derivative · entry 1 Bazemore Robert B · CIK 0001620152 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 292,983 Underlying: Class A Common Stock · 292,983 shares Expires 2035-05-20 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 21, 2025); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date. Read SEC document |
| March 20, 2025 Filed Mar 24, 2025 21:00 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantStock Option (Right to Buy) · Derivative | 225,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0000950170-25-043939 · ownership.xml · derivative · entry 3 Bazemore Robert B · CIK 0001620152 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,000 Underlying: American Depositary Shares representing Ordinary Shares · 225,000 shares Expires 2035-03-20 F3 · derivative.exercise_date: The stock option award was granted under the Issuer's 2023 Equity Incentive Plan. Subject to the Reporting Person's continued service with the Issuer and shareholder approval covering the issuance of the ADS underlying this stock option, this option shall vest (i) 25% on the grant date (ii) 25% on December 31, 2025 and (iii) the remaining 50% shall vest ratably on a monthly basis over the 24 month period thereafter. F1 · derivative.underlying: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer. Read SEC document |
| March 20, 2025 Filed Mar 24, 2025 21:00 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantStock Option (Right to Buy) · Derivative | 175,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0000950170-25-043939 · ownership.xml · derivative · entry 2 Bazemore Robert B · CIK 0001620152 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,000 Underlying: American Depositary Shares representing Ordinary Shares · 175,000 shares Expires 2035-03-20 F2 · derivative.exercise_date: The stock option award was granted under the Issuer's 2023 Equity Incentive Plan. The stock option shall vest over four years from the grant date with 25% vesting on the 12 month anniversary of the grant date, and the remainder vesting ratably on a monthly basis over the then remaining 36 months from the grant date, such that it will be fully vested on the fourth anniversary of the grant date. The stock option award is subject to continued service with the Issuer. F1 · derivative.underlying: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 21:00 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantSeries B Warrants (Right to Buy) · Derivative | 44,642 | $1.12 Strike: $0.87 | $49,999.04 |
DisclosureSEC source: 0000950170-25-036482 · ownership.xml · derivative · entry 3 Bazemore Robert B · CIK 0001620152 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,642 Underlying: American Depositary Shares representing Ordinary Shares · 44,642 shares Expires 2030-03-06 F2 · kind: On March 6, 2025, the Reporting Person acquired 44,642 ADS and accompanying Series A and Series B warrants to purchase up to 89,284 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant. F2 · price: On March 6, 2025, the Reporting Person acquired 44,642 ADS and accompanying Series A and Series B warrants to purchase up to 89,284 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant. F1 · derivative.underlying: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 21:00 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantSeries A Warrants (Right to Buy) · Derivative | 44,642 | $1.12 Strike: $0.87 | $49,999.04 |
DisclosureSEC source: 0000950170-25-036482 · ownership.xml · derivative · entry 2 Bazemore Robert B · CIK 0001620152 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,642 Underlying: American Depositary Shares representing Ordinary Shares · 44,642 shares Expires 2026-03-06 F2 · kind: On March 6, 2025, the Reporting Person acquired 44,642 ADS and accompanying Series A and Series B warrants to purchase up to 89,284 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant. F2 · price: On March 6, 2025, the Reporting Person acquired 44,642 ADS and accompanying Series A and Series B warrants to purchase up to 89,284 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant. F1 · derivative.underlying: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 21:00 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantAmerican Depositary Shares representing Ordinary Shares | 44,642 | $1.12 | $49,999.04 |
DisclosureSEC source: 0000950170-25-036482 · ownership.xml · nonDerivative · entry 1 Bazemore Robert B · CIK 0001620152 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,642 F1 · security: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer. F2 · kind: On March 6, 2025, the Reporting Person acquired 44,642 ADS and accompanying Series A and Series B warrants to purchase up to 89,284 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant. F2 · price: On March 6, 2025, the Reporting Person acquired 44,642 ADS and accompanying Series A and Series B warrants to purchase up to 89,284 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant. Read SEC document |
| September 17, 2024 Filed Sep 18, 2024 20:40 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantStock Option (Right to Buy) · Derivative | 5,000,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-107828 · ownership.xml · derivative · entry 1 Bazemore Robert B · CIK 0001620152 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000,000 Underlying: Ordinary Shares, par value $0.0001 per share · 5,000,000 shares Expires 2034-09-17 F1 · derivative.exercise_price: The stock options have an exercise price of $0.001655 per ordinary share, par value $0.0001 per share ("Ordinary Share"). F2 · derivative.exercise_date: Non-qualified stock option granted under the Issuer's 2023 Equity Incentive Plan. The stock option vests and becomes exercisable ratably in three equal installments with the first installment vesting on the date of the first Annual General Meeting ("AGM") following the date of the grant, and with the second and third installments vesting, respectively, on the dates of the second and third AGM's following the date of the grant, subject to the non-employee director's continued service with the Issuer. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 21:55 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantStock Option (Right to Buy) · Derivative | 200,801 | $0.00 Strike: $2.98 | $0.00 |
DisclosureSEC source: 0001415889-24-022965 · form4-09052024_090950.xml · derivative · entry 1 Bazemore Robert B · CIK 0001620152 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,801 Underlying: Class A Common Stock · 200,801 shares Expires 2034-09-02 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (September 3, 2024); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date. Read SEC document |
| June 14, 2024 Filed Jun 17, 2024 22:48 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 40,243 | $0.00 Strike: $6.35 | $0.00 |
DisclosureSEC source: 0001628280-24-028596 · wk-form4_1718664529.xml · derivative · entry 1 Bazemore Robert B · CIK 0001620152 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,243 Underlying: Common Stock · 40,243 shares Expires 2034-06-14 F1 · shares: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F2 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 22:28 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 49,237 | $0.00 Strike: $3.92 | $0.00 |
DisclosureSEC source: 0001628280-23-022552 · wk-form4_1686954498.xml · derivative · entry 1 Bazemore Robert B · CIK 0001620152 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,237 Underlying: Common Stock · 49,237 shares Expires 2033-06-15 F1 · shares: The shares were issued pursuant to the Issuer's Non-Employee Director Compensation Program. F2 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. Read SEC document |
| May 15, 2023 Filed May 17, 2023 21:04 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantStock Option (Right to Buy) · Derivative | 366,744 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001209191-23-030259 · doc4.xml · derivative · entry 1 Bazemore Robert B · CIK 0001620152 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 366,744 Underlying: Class A Common Stock · 366,744 shares Expires 2033-05-14 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 15, 2024); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 20:23 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0001567619-22-013087 · doc1.xml · derivative · entry 1 Bazemore Robert B · CIK 0001620152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-06-15 F1 · shares: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F2 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:57 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantStock Option (Right to Buy) · Derivative | 118,784 | $0.00 Strike: $4.05 | $0.00 |
DisclosureSEC source: 0001209191-22-030091 · doc4.xml · derivative · entry 1 Bazemore Robert B · CIK 0001620152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,784 Underlying: Class A Common Stock · 118,784 shares Expires 2032-05-15 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 16, 2023); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date. Read SEC document |
| May 16, 2022 Filed Jun 28, 2022 23:07 UTC Amendment | Nuvation Bio Inc. NUVB · Entity 4384 | GrantStock Option (Right to Buy) · Derivative | 140,713 | $0.00 Strike: $4.05 | $0.00 |
DisclosureSEC source: 0001209191-22-039676 · doc4a.xml · derivative · entry 1 Bazemore Robert B · CIK 0001620152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,713 Underlying: Class A Common Stock · 140,713 shares Expires 2032-05-15 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 16, 2023); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date. Read SEC document |
| October 29, 2021 Filed Nov 3, 2021 01:29 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantStock Option (Right to Buy) · Derivative | 45,229 | $0.00 Strike: $9.17 | $0.00 |
DisclosureSEC source: 0001209191-21-062585 · doc4.xml · derivative · entry 1 Bazemore Robert B · CIK 0001620152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,229 Underlying: Class A Common Stock · 45,229 shares Expires 2031-10-28 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (October 29, 2022); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 20:10 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 32,765 | $0.00 Strike: $7.31 | $0.00 |
DisclosureSEC source: 0001567619-21-012430 · doc1.xml · derivative · entry 1 Bazemore Robert B · CIK 0001620152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,765 Underlying: Common Stock · 32,765 shares Expires 2031-06-16 F1 · shares: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F2 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 21:16 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | PurchaseClass A Common Stock | 5,000 | $9.98 | $49,899.50 |
DisclosureSEC source: 0001209191-21-024159 · doc4.xml · nonDerivative · entry 1 Bazemore Robert B · CIK 0001620152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
| March 25, 2021 Filed Mar 29, 2021 16:30 UTC | Epizyme, Inc. EPZM · Entity 12703 | SaleCommon Stock, par value $0.0001 | 10,328 | $7.85 | $81,074.80 |
DisclosureSEC source: 0000899243-21-013804 · doc4.xml · nonDerivative · entry 1 Bazemore Robert B · CIK 0001620152 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 322,626 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted under the Issuer's 2013 Stock Incentive Plan on March 24, 2020. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the reporting person. F2 · balance_after: The Reporting Person acquired 977 shares of common stock under the Issuer's 2013 Employee Stock Purchase Plan on February 28, 2021. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 22:53 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantStock Option (Right to Buy) · Derivative | 187,658 | Not disclosed Strike: $1.74 | Not disclosed |
DisclosureSEC source: 0001209191-21-010354 · doc4.xml · derivative · entry 2 Bazemore Robert B · CIK 0001620152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,658 Underlying: Class A Common Stock · 187,658 shares Expires 2030-07-21 F1 · kind: Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer"). F5 · price: Received in exchange for an option to purchase 187,392 shares of Legacy Nuvation Class A Common Stock. F4 · derivative.exercise_date: Options vest in 48 equal monthly installments from July 22, 2020. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 22:53 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantStock Option (Right to Buy) · Derivative | 51,703 | Not disclosed Strike: $4.60 | Not disclosed |
DisclosureSEC source: 0001209191-21-010354 · doc4.xml · derivative · entry 1 Bazemore Robert B · CIK 0001620152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,703 Underlying: Class A Common Stock · 51,703 shares Expires 2030-10-04 F1 · kind: Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer"). F3 · price: Received in exchange for an option to purchase 51,630 shares of Legacy Nuvation Class A Common Stock. F2 · derivative.exercise_date: Options vest in 48 equal monthly installments from October 5, 2020. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 16:41 UTC | Epizyme, Inc. EPZM · Entity 12703 | SaleCommon Stock, par value $0.0001 | 3,890 | $11.21 | $43,606.90 |
DisclosureSEC source: 0000899243-21-005044 · doc4.xml · nonDerivative · entry 1 Bazemore Robert B · CIK 0001620152 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,977 F1 · shares: Represents shares automatically sold by the reporting person to satisfy tax withholding obligations in connection with the vesting of the restricted stock units granted under the issuer's 2013 Stock Incentive Plan on February 3, 2020. The automatic sale of the reporting person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the reporting person. Read SEC document |
| February 01, 2021 Filed Feb 2, 2021 21:09 UTC | Epizyme, Inc. EPZM · Entity 12703 | GrantStock Option (Right to Buy) · Derivative | 417,443 | $0.00 Strike: $11.02 | $0.00 |
DisclosureSEC source: 0000899243-21-004523 · doc4.xml · derivative · entry 2 Bazemore Robert B · CIK 0001620152 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 417,443 Underlying: Common Stock · 417,443 shares Expires 2031-01-31 F2 · derivative.exercise_date: This option was granted on February 1, 2021 pursuant to the Company's 2013 Stock Incentive Plan with respect to 417,443 shares of Common Stock, with 25% vesting on February 1, 2022 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| February 01, 2021 Filed Feb 2, 2021 21:09 UTC | Epizyme, Inc. EPZM · Entity 12703 | GrantCommon Stock | 87,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-004523 · doc4.xml · nonDerivative · entry 1 Bazemore Robert B · CIK 0001620152 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,867 F1 · shares: Consists of shares of Common Stock issuable under 87,500 restricted stock units ("RSUs") granted pursuant to the Company's 2013 Stock Incentive Plan. Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in four equal annual installments over four years from the grant date, with the first installment vesting on February 1, 2022. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 20:44 UTC | Epizyme, Inc. EPZM · Entity 12703 | SaleCommon Stock, par value $0.0001 | 6,069 | $11.41 | $69,247.29 |
DisclosureSEC source: 0000899243-21-003535 · doc4.xml · nonDerivative · entry 1 Bazemore Robert B · CIK 0001620152 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,367 F1 · shares: Represents shares automatically sold by the reporting person to satisfy tax withholding obligations in connection with the vesting of the restricted stock units granted under the issuer's 2013 Stock Incentive Plan on January 24, 2019. The automatic sale of the reporting person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the reporting person. F2 · balance_after: The reporting person acquired (i) 708 shares of Common Stock under the Issuer's 2013 Employee Stock Purchase Plan (the "2013 ESPP") on August 31, 2018, (ii) 1,120 shares of Common Stock under the 2013 ESPP on February 28, 2019, (iii) 971 shares of Common Stock under the 2013 ESPP on August 31, 2019, and (iv) 996 shares of Common Stock under the 2013 ESPP on February 29, 2020 that were not previously reported on Form 4. F3 · balance_after: The reporting person acquired 543 shares of Common Stock under the 2013 ESPP on August 31, 2020. Read SEC document |
| June 26, 2020 Filed Jun 30, 2020 09:01 UTC | Epizyme, Inc. EPZM · Entity 12703 | SaleCommon Stock, par value $0.0001 | 4,773 | $16.15 | $77,083.95 |
DisclosureSEC source: 0000899243-20-017904 · doc4.xml · nonDerivative · entry 2 Bazemore Robert B · CIK 0001620152 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,098 F2 · shares: Represents shares automatically sold by the reporting person to satisfy tax withholding obligations in connection with the vesting of the restricted stock units described in footnote 1. The automatic sale of the reporting person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the reporting person. Read SEC document |
| June 25, 2020 Filed Jun 30, 2020 09:01 UTC | Epizyme, Inc. EPZM · Entity 12703 | GrantCommon Stock, par value $0.0001 | 10,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-017904 · doc4.xml · nonDerivative · entry 1 Bazemore Robert B · CIK 0001620152 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,871 F1 · price: Represents common stock issued upon vesting of restricted stock units granted under the issuer's 2013 Stock Incentive Plan that vested upon the issuer's achievement of a specified performance target. The transaction date represents the date on which the issuer's Compensation Committee determined that the performance target was achieved. Read SEC document |
| June 18, 2020 Filed Jun 22, 2020 19:36 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $8.98 | $0.00 |
DisclosureSEC source: 0000899243-20-017444 · doc4.xml · derivative · entry 4 Bazemore Robert B · CIK 0001620152 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323,333 Underlying: Common Stock · 10,000 shares Expires 2026-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · derivative.exercise_date: This option is fully vested. Read SEC document |
| June 18, 2020 Filed Jun 22, 2020 19:36 UTC | Epizyme, Inc. EPZM · Entity 12703 | SaleCommon Stock, par value $0.0001 | 10,000 | $22.00 | $220,000.00 |
DisclosureSEC source: 0000899243-20-017444 · doc4.xml · nonDerivative · entry 3 Bazemore Robert B · CIK 0001620152 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,371 F3 · kind: Represents the sale of shares held by the Reporting Person. Read SEC document |
| June 18, 2020 Filed Jun 22, 2020 19:36 UTC | Epizyme, Inc. EPZM · Entity 12703 | SaleCommon Stock, par value $0.0001 | 10,000 | $22.00 | $220,000.00 |
DisclosureSEC source: 0000899243-20-017444 · doc4.xml · nonDerivative · entry 2 Bazemore Robert B · CIK 0001620152 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,371 F2 · kind: Represents the sale of shares acquired by the Reporting Person upon the exercise of options described in Table II to this Form 4. Read SEC document |
| June 18, 2020 Filed Jun 22, 2020 19:36 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionCommon Stock, par value $0.0001 | 10,000 | $8.98 | $89,800.00 |
DisclosureSEC source: 0000899243-20-017444 · doc4.xml · nonDerivative · entry 1 Bazemore Robert B · CIK 0001620152 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,371 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 22:19 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 23,500 | $0.00 Strike: $7.31 | $0.00 |
DisclosureSEC source: 0001567619-20-012028 · doc1.xml · derivative · entry 1 Bazemore Robert B · CIK 0001620152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock · 23,500 shares Expires 2030-06-09 F1 · shares: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F2 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. Read SEC document |
| May 06, 2020 Filed May 6, 2020 21:07 UTC | Neon Therapeutics, Inc. NTGN · Entity 149433 | Disposition to issuerStock Option (Right to Buy) · Derivative | 18,500 | Not disclosed Strike: $4.64 | Not disclosed |
DisclosureSEC source: 0001694187-20-000066 · wf-form4_158881361091900.xml · derivative · entry 2 Bazemore Robert B · CIK 0001620152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,500 shares Expires not disclosed F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 15, 2020, by and among the Issuer, BioNTech SE ("BioNTech"), and Endor Lights, Inc. a direct wholly owned subsidiary of BioNTech ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of May 6, 2020 (the "Effective Time"), at the Effective Time these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration"). F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 15, 2020, by and among the Issuer, BioNTech SE ("BioNTech"), and Endor Lights, Inc. a direct wholly owned subsidiary of BioNTech ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of May 6, 2020 (the "Effective Time"), at the Effective Time these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration"). F1 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 15, 2020, by and among the Issuer, BioNTech SE ("BioNTech"), and Endor Lights, Inc. a direct wholly owned subsidiary of BioNTech ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of May 6, 2020 (the "Effective Time"), at the Effective Time these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration"). Read SEC document |
| May 06, 2020 Filed May 6, 2020 21:07 UTC | Neon Therapeutics, Inc. NTGN · Entity 149433 | Disposition to issuerStock Option (Right to Buy) · Derivative | 28,000 | Not disclosed Strike: $7.56 | Not disclosed |
DisclosureSEC source: 0001694187-20-000066 · wf-form4_158881361091900.xml · derivative · entry 1 Bazemore Robert B · CIK 0001620152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,000 shares Expires not disclosed F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 15, 2020, by and among the Issuer, BioNTech SE ("BioNTech"), and Endor Lights, Inc. a direct wholly owned subsidiary of BioNTech ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of May 6, 2020 (the "Effective Time"), at the Effective Time these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration"). F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 15, 2020, by and among the Issuer, BioNTech SE ("BioNTech"), and Endor Lights, Inc. a direct wholly owned subsidiary of BioNTech ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of May 6, 2020 (the "Effective Time"), at the Effective Time these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration"). F1 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 15, 2020, by and among the Issuer, BioNTech SE ("BioNTech"), and Endor Lights, Inc. a direct wholly owned subsidiary of BioNTech ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of May 6, 2020 (the "Effective Time"), at the Effective Time these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration"). Read SEC document |
| March 25, 2020 Filed Mar 26, 2020 21:00 UTC | Epizyme, Inc. EPZM · Entity 12703 | SaleCommon Stock, par value $0.0001 | 3,285 | $15.28 | $50,194.80 |
DisclosureSEC source: 0000899243-20-009605 · doc4.xml · nonDerivative · entry 4 Bazemore Robert B · CIK 0001620152 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,371 F4 · shares: Represents shares automatically sold by the reporting person to satisfy tax withholding obligations in connection with the vesting of the restricted stock units described in footnote 6. The automatic sale of the reporting person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the reporting person. Read SEC document |
| March 24, 2020 Filed Mar 26, 2020 21:00 UTC | Epizyme, Inc. EPZM · Entity 12703 | GrantStock Option (Right to Buy) · Derivative | 73,409 | $0.00 Strike: $16.14 | $0.00 |
DisclosureSEC source: 0000899243-20-009605 · doc4.xml · derivative · entry 8 Bazemore Robert B · CIK 0001620152 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,409 Underlying: Common Stock · 73,409 shares Expires 2030-03-23 F1 · shares: Represents the portion of stock options and restricted stock units granted to Mr. Bazemore that inadvertently were granted in excess of the annual per participant limit under the Company's 2013 Stock Incentive Plan and have been rescinded. The Company has granted to Mr. Bazemore the referenced stock options (see footnote 8) and restricted stock units (see footnote 2) to replace the fair value of the rescinded stock options and restricted stock units and provide Mr. Bazemore with the equity incentive compensation that Mr. Bazemore was intended to receive with the rescinded grants. F8 · derivative.exercise_date: This stock option was granted on March 24, 2020 under the Company's 2013 Stock Incentive Plan and (i) is vested in full with respect to 44,047 shares, (ii) vests in full on February 8, 2021 with respect to 1,829 shares and (iii) with respect to the remaining 27,533 shares of common stock, vests in seven substantially equal monthly installments, with the first installment vesting on June 24, 2022 and the last installment vesting on December 24, 2022. Read SEC document |
| March 24, 2020 Filed Mar 26, 2020 21:00 UTC | Epizyme, Inc. EPZM · Entity 12703 | OtherStock Option (Right to Buy) · Derivative | 48,727 | $0.00 Strike: $9.12 | $0.00 |
DisclosureSEC source: 0000899243-20-009605 · doc4.xml · derivative · entry 7 Bazemore Robert B · CIK 0001620152 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,737 Underlying: Common Stock · 48,727 shares Expires 2029-01-23 F1 · shares: Represents the portion of stock options and restricted stock units granted to Mr. Bazemore that inadvertently were granted in excess of the annual per participant limit under the Company's 2013 Stock Incentive Plan and have been rescinded. The Company has granted to Mr. Bazemore the referenced stock options (see footnote 8) and restricted stock units (see footnote 2) to replace the fair value of the rescinded stock options and restricted stock units and provide Mr. Bazemore with the equity incentive compensation that Mr. Bazemore was intended to receive with the rescinded grants. F7 · derivative.exercise_date: The remaining stock options, which were originally granted to Mr. Bazemore on January 24, 2019, are vested with respect to 101,343 shares, with (i) 188,210 of the remaining unvested shares vesting in 26 substantially equal monthly installments from April 24, 2020 through May 24, 2022 (ii) 1,945 of the remaining unvested shares vesting on June 24, 2022 and (iii) 7,239 of the remaining unvested shares vesting on January 24, 2023. Read SEC document |
| March 24, 2020 Filed Mar 26, 2020 21:00 UTC | Epizyme, Inc. EPZM · Entity 12703 | OtherStock Option (Right to Buy) · Derivative | 2,371 | $0.00 Strike: $12.45 | $0.00 |
DisclosureSEC source: 0000899243-20-009605 · doc4.xml · derivative · entry 6 Bazemore Robert B · CIK 0001620152 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,333 Underlying: Common Stock · 2,371 shares Expires 2027-02-07 F1 · shares: Represents the portion of stock options and restricted stock units granted to Mr. Bazemore that inadvertently were granted in excess of the annual per participant limit under the Company's 2013 Stock Incentive Plan and have been rescinded. The Company has granted to Mr. Bazemore the referenced stock options (see footnote 8) and restricted stock units (see footnote 2) to replace the fair value of the rescinded stock options and restricted stock units and provide Mr. Bazemore with the equity incentive compensation that Mr. Bazemore was intended to receive with the rescinded grants. F6 · derivative.exercise_date: The remaining stock options, which were originally granted to Mr. Bazemore on February 8, 2017, are vested with respect to 258,771 shares, with (i) 69,939 of the remaining unvested shares vesting in ten substantially equal monthly installments from April 8, 2020 through January 8, 2021 and (ii) 4,623 of the remaining shares vesting on February 8, 2021. Read SEC document |
| March 24, 2020 Filed Mar 26, 2020 21:00 UTC | Epizyme, Inc. EPZM · Entity 12703 | OtherStock Option (Right to Buy) · Derivative | 79,167 | $0.00 Strike: $8.98 | $0.00 |
DisclosureSEC source: 0000899243-20-009605 · doc4.xml · derivative · entry 5 Bazemore Robert B · CIK 0001620152 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,333 Underlying: Common Stock · 79,167 shares Expires 2026-02-07 F1 · shares: Represents the portion of stock options and restricted stock units granted to Mr. Bazemore that inadvertently were granted in excess of the annual per participant limit under the Company's 2013 Stock Incentive Plan and have been rescinded. The Company has granted to Mr. Bazemore the referenced stock options (see footnote 8) and restricted stock units (see footnote 2) to replace the fair value of the rescinded stock options and restricted stock units and provide Mr. Bazemore with the equity incentive compensation that Mr. Bazemore was intended to receive with the rescinded grants. F5 · derivative.exercise_date: The remaining stock options, which were originally granted to Mr. Bazemore on February 8, 2016, have vested in full. Read SEC document |
| March 24, 2020 Filed Mar 26, 2020 21:00 UTC | Epizyme, Inc. EPZM · Entity 12703 | GrantCommon Stock, par value $0.0001 | 7,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-009605 · doc4.xml · nonDerivative · entry 3 Bazemore Robert B · CIK 0001620152 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,656 F3 · shares: Represents common stock issued upon vesting of restricted stock units granted under the issuer's 2013 Stock Incentive Plan that vested upon the issuer's achievement of a specified performance target. The transaction date represents the date on which the issuer's Compensation Committee determined that the performance target was achieved. Read SEC document |
| March 24, 2020 Filed Mar 26, 2020 21:00 UTC | Epizyme, Inc. EPZM · Entity 12703 | GrantCommon Stock, par value $0.0001 | 113,393 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-009605 · doc4.xml · nonDerivative · entry 2 Bazemore Robert B · CIK 0001620152 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,656 F1 · shares: Represents the portion of stock options and restricted stock units granted to Mr. Bazemore that inadvertently were granted in excess of the annual per participant limit under the Company's 2013 Stock Incentive Plan and have been rescinded. The Company has granted to Mr. Bazemore the referenced stock options (see footnote 8) and restricted stock units (see footnote 2) to replace the fair value of the rescinded stock options and restricted stock units and provide Mr. Bazemore with the equity incentive compensation that Mr. Bazemore was intended to receive with the rescinded grants. F2 · shares: Consists of shares of common stock issuable under restricted stock units granted pursuant to the Company's 2013 Stock Incentive Plan. Each restricted stock unit represents the right to receive one share of common stock upon vesting. 56,537 of the restricted stock units are scheduled to vest in three equal annual installments on January 24, 2021, January 24, 2022 and January 24, 2023. The balance of the restricted stock units are scheduled to vest in two equal annual installments over two years from the grant date. Read SEC document |
| March 24, 2020 Filed Mar 26, 2020 21:00 UTC | Epizyme, Inc. EPZM · Entity 12703 | OtherCommon Stock, par value $0.0001 | 56,537 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-009605 · doc4.xml · nonDerivative · entry 1 Bazemore Robert B · CIK 0001620152 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,726 F1 · shares: Represents the portion of stock options and restricted stock units granted to Mr. Bazemore that inadvertently were granted in excess of the annual per participant limit under the Company's 2013 Stock Incentive Plan and have been rescinded. The Company has granted to Mr. Bazemore the referenced stock options (see footnote 8) and restricted stock units (see footnote 2) to replace the fair value of the rescinded stock options and restricted stock units and provide Mr. Bazemore with the equity incentive compensation that Mr. Bazemore was intended to receive with the rescinded grants. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.